Everolimus in advanced, progressive, well‐differentiated, non‐functional neuroendocrine tumors: RADIANT‐4 lung subgroup analysis

In the phase III RADIANT‐4 study, everolimus improved median progression‐free survival (PFS) by 7.1 months in patients with advanced, progressive, well‐differentiated (grade 1 or grade 2), non‐functional lung or gastrointestinal neuroendocrine tumors (NETs) vs placebo (hazard ratio, 0.48; 95% confid...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Cancer Sci
Main Authors: Fazio, Nicola, Buzzoni, Roberto, Delle Fave, Gianfranco, Tesselaar, Margot E., Wolin, Edward, Van Cutsem, Eric, Tomassetti, Paola, Strosberg, Jonathan, Voi, Maurizio, Bubuteishvili‐Pacaud, Lida, Ridolfi, Antonia, Herbst, Fabian, Tomasek, Jiri, Singh, Simron, Pavel, Marianne, Kulke, Matthew H., Valle, Juan W., Yao, James C.
Formato: Artigo
Idioma:Inglês
Publicado: John Wiley and Sons Inc. 2017
Assuntos:
Original Articles
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC5765303/
https://ncbi.nlm.nih.gov/pubmed/29055056
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cas.13427
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares